ArticleNature medicine2026
Innate antiviral and immune functions associated with the HIV reservoir decay after anti-PD-1 therapy.
Abstract readClinical Trial, Phase I
In one paragraph
Article in Nature medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- The Immune Checkpoint Inhibitors Journey: From Early Promise to Lasting Impact.Journal of immunotherapy and precision oncology · 2026Review
- Intragenic transcription from defective HIV proviruses triggers interferon responses in myeloid cells.Journal of virology · 2026Article
- In vivo effect of anti-PD-1 on HIV-specific CD8+T-cells in men with HIV.Nature communications · 2026Article
- Natural killer cells against viral infection: from basic biology to immunotherapy.Precision clinical medicine · 2026Review
- Review
- Intragenic Transcription from Defective HIV Proviruses Triggers Interferon Responses in Myeloid Cells.bioRxiv : the preprint server for biology · 2026Article
- Unveiling the role of extracellular vesicles in HIV infection: molecular mechanisms, viral persistence, and therapeutic opportunities.FEMS microbiology reviews · 2026Review
- Immune checkpoint inhibitors in HIV infection: current evidence on viral reservoir regulation and immune restoration.Frontiers in immunology · 2026Review
- Immune checkpoint inhibitors in infectious diseases: therapeutic reinvigoration, immunopathology, and precision targeting.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors.
Aarthi Talla *Immunasyst, Phoenix, AZ, USA.
Joao L L C Azevedo *Pathology Advanced Translational Research Unit, Department of Pathology, Emory University, School of Medicine, Atlanta, GA, USA.
Muhammad Bilal LatifPathology Advanced Translational Research Unit, Department of Pathology, Emory University, School of Medicine, Atlanta, GA, USA.
Ana B EnriquezPathology Advanced Translational Research Unit, Department of Pathology, Emory University, School of Medicine, Atlanta, GA, USA.
Gabriela Pacheco SanchezDepartment of Biology, West Virginia University, Morgantown, WV, USA.
Adam N PelletierRPM Bioinfo Solutions, Montreal, Quebec, Canada.
Saswat Kumar BalSignios Biosciences, Inc., Foster City, CA, USA.
Sangeeta KumariTakara Bio USA, Inc., San Jose, CA, USA.
Viviane SchuchDepartment of Microbiology, Biochemistry and Immunology, Morehouse School of Medicine, Atlanta, GA, USA.
Khader GhneimPathology Advanced Translational Research Unit, Department of Pathology, Emory University, School of Medicine, Atlanta, GA, USA.
Ajantha RhodesDepartment of Infectious Diseases, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
Frank MaldarelliHIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.ORCID http://orcid.org/0000-0002-3062-5250
Robert YarchoanHIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.ORCID http://orcid.org/0000-0002-3057-1395
Kathryn LurainDivision of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
Ramya RamaswamiHIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.ORCID http://orcid.org/0000-0001-5709-4675
Elad SharonDana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0002-0044-9719
Bruce W HessFred Hutchinson Cancer Center, Seattle, WA, USA.
Leonard D'AmicoFred Hutchinson Cancer Center, Seattle, WA, USA.ORCID http://orcid.org/0000-0002-1143-7297
Javier Martinez-PicadoIrsiCaixa, Barcelona, Spain.ORCID http://orcid.org/0000-0002-4916-2129
Nicolas ChomontDepartment of Microbiology, Infectiology, and Immunology, Université de Montréal and Centre de Recherche du CHUM, Montreal, Quebec, Canada.ORCID http://orcid.org/0000-0001-9747-5018
Sharon R LewinDepartment of Infectious Diseases, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.ORCID http://orcid.org/0000-0002-0330-8241
Steven G DeeksUniversity of California, San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0001-6371-747X
Steven P FlingFred Hutchinson Cancer Center, Seattle, WA, USA.ORCID http://orcid.org/0000-0001-6263-0153
Martin A CheeverFred Hutchinson Cancer Center, Seattle, WA, USA.
Thomas S UldrickFred Hutchinson Cancer Center, Seattle, WA, USA.
Ashish A SharmaPathology Advanced Translational Research Unit, Department of Pathology, Emory University, School of Medicine, Atlanta, GA, USA.ORCID http://orcid.org/0000-0001-9444-7046
Rafick-Pierre SekalyPathology Advanced Translational Research Unit, Department of Pathology, Emory University, School of Medicine, Atlanta, GA, USA. rafick.sekaly@emory.edu.ORCID http://orcid.org/0000-0002-7816-4828
Funding
Virology and Molecular Biomarkers CoreP30AI050409 · NIAID · EMORY UNIVERSITY · PI Ann M Chahroudi, Colleen F Kelley · 2002 to 2026
$74.0MReversing Immune Dysfunction for HIV-1 EradicationUM1AI164561 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI SUMIT K CHANDA, Paula M Cannon · 2021 to 2026
$30.0MMultiOMICS to uncover immune and virological mechanisms that drive HIV DNA decay, restore immune homeostasis, and promote HIV specific immunity in PWH receiving cell therapies.P01AI178376 · NIAID · EMORY UNIVERSITY · PI Rafick Pierre Sekaly · 2023 to 2026
$6.1MNIAID NIH HHS P30 AI050409U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) P01AI178376U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) UM1AI164561
Abstract
Antiretroviral therapy (ART) suppresses HIV but does not eliminate the latent viral reservoir, which persists in programmed cell death protein 1 (PD-1)-expressing CD4
Indexed as
Antibodies, Monoclonal, HumanizedHIV-1HIV InfectionsImmunity, InnateNeoplasmsProgrammed Cell Death 1 ReceptorAdultCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesFemaleHumansMaleMiddle AgedViral LoadVirus LatencyAntibodies, Monoclonal, HumanizedPDCD1 protein, humanpembrolizumabProgrammed Cell Death 1 Receptor
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.